Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2558949 | 0.80 | USP2 (0.39) | USP2SLCO1B1PDE4A | |
| SCHEMBL3642844 | 0.80 | USP2 (0.39) | USP2SLCO1B1PDE4A | |
| SCHEMBL4388015 | 0.75 | USP2 (0.47) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL2346239 | 0.74 | USP2 (0.36) | USP2SLCO1B1 | |
| SCHEMBL28914 | 0.72 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL149462 | 0.72 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL28138343 | 0.72 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL21057 | 0.72 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL9360028 | 0.72 | USP2 (0.47) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Serine SCHEMBL1898151 | 0.71 | PDE4A (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661543-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | Vasculonics LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2020082057-A1 | INTERLEUKIN-10 POLYPEPTIDE CONJUGATES, DIMERS THEREOF, AND THEIR USES | AMBRX, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019028040-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | VASCULONICS LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2615108-B1 | Modified human plasma polypeptide or fc scaffolds and thier uses | AMBRX INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2820034-A1 | MODIFIED ADIPONECTIN POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2820033-A1 | INTERLEUKIN-10 POLYPEPTIDE CONJUGATES AND THEIR USES | Ambrx, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130913-A1 | INTERLEUKIN-10 POLYPEPTIDE CONJUGATES AND THEIR USES | AMBRX, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130676-A1 | MODIFIED ADIPONECTIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2011079293-A1 | TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND POLYPEPTIDES AND THEIR USES | AMBRX, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| EP-2318029-A2 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-1718339-A4 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008030558-A2 | MODIFIED HUMAN PLASMA POLYPEPTIDE OR FC SCAFFOLDS AND THEIR USES | AMBRX, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-1893229-A2 | IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES | Ambrx, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1836314-A2 | MODIFIED HUMAN GROWTH HORMONE | Ambrx, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069220-A9 | MODIFIED HUMAN GROWTH HORMONE | AMBRX INC (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006133088-A2 | IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES | AMBRX, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006133089-A2 | IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES | AMBRX, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1718339-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006069220-A2 | MODIFIED HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005074524-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |